GI Cancers

Nivolumab Plus Chemotherapy Extends PFS With Durable Responses in Gastric/GEJ Cancers

September 21, 2020

In the phase 3 ATTRACTION-4 study, nivolumab added to chemotherapy led to a statistically significant improvement in progression-free survival and induced higher overall response rates in patients with previously untreated advanced or recurrent gastric and gastroesophageal junction cancer, according to results presented during the 2020 ESMO Virtual Congress.

Significant PFS Benefit Observed With Surufatinib in Pancreatic NETs

September 21, 2020

A statistically significant and clinically meaningful improvement in progression-free survival was observed with the use of surufatinib compared with placebo in patients with advanced pancreatic neuroendocrine tumors, meeting the primary end point of the randomized phase 3 SANET-p study.

Lanreotide Autogel Dosed More Frequently Delays More Toxic Regimens in Pancreatic, Midgut NETs

September 19, 2020

For patients with progressive pancreatic or midgut neuroendocrine tumors, improvements in disease-free survival and progression-free survival were seen when the dosing of lanreotide Autogel was increased from 120 mg every 28 days to every 14 days. Data from the phase 2 CLARINET FORTE study suggest that this treatment option can delay switching to a more toxic treatment, which was presented at the 2020 ESMO Virtual Congress.

Futibatinib Induces Durable Responses in FGFR2+ Intrahepatic Cholangiocarcinoma

September 18, 2020

Futibatinib demonstrated efficacy and tolerability when administered as treatment of patients with intrahepatic cholangiocarcinoma who harbor FGFR2 fusions/rearrangements, according to interim analysis results presented in a poster during the the European Society of Medical Oncology Virtual Congress 2020

Doctors Debate: Should Perioperative Treatment of GEJ/Gastric Cancer Include Radiotherapy?

August 24, 2020

During a debate at the 2020 Debates and Didactics in Hematology and Oncology Conference, Mehmet Akce, MD and Pretesh Patel, MD, argued their position on whether perioperative therapy for GEJ/gastric cancers should include radiation.

Dabrafenib Plus Trametinib Phase 2 Data Inspire Hope for Targeted Therapy in Biliary Tract Cancer

August 19, 2020

Vivek Subbiah, MD, discussed the positive findings from the phase 2 ROAR clinical trial, which evaluated the targeted therapy combination of dabrafenib and trametinib as treatment of patients with cholangiocarcinoma harboring a BRAF V600E mutation.

KEYNOTE-590 Demonstrates OS Benefit With Pembrolizumab Plus Chemotherapy in Advanced Esophageal Cancer

August 19, 2020

The primary end point of the phase 3 KEYNOTE-590 trial was met when the combination of pembrolizumab and chemotherapy improved overall survival (OS) and progression-free survival as initial treatment of patients with locally advanced or metastatic esophageal cancer during an interim analysis of the study.

Pembrolizumab Combo Extends Chemotherapy Benefit in Pancreatic Cancer

August 12, 2020

Positive data from the phase IIa COMBAT clinical trial indicate that CXCR4 and PD-1 blockade with the combination of pembrolizumab and BL-8040 can improved upon the benefit of chemotherapy as treatment of pancreatic ductal adenocarcinoma.